ESC 2017: Renal-Denervation Redux? Medtronic Plans A New Pivotal Study Following Positive Data

28 Aug 2017

• By David Filmore

Medtronic is re-upping its investments into renal denervation to treat hypertension after interim results were positive from a study testing the device procedure in patients not taking antihypertensive drugs. The firm announced it is launching a new pivotal study, more than three-and-a-half years after its last pivotal trial in the space failed.

After several years of second-guessing in the medical community, Medtronic has reported a positive development toward restoring renal denervation's prospects as a promising treatment option for hypertension.

A statistically significant reduction in blood pressure was found from renal denervation in sham-controlled, three-month data from 80 patients presented...